↓ Skip to main content

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma

Overview of attention for article published in Transplantation and Cellular Therapy, March 2018
Altmetric Badge

Mentioned by

twitter
7 X users

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
37 Mendeley